Nebivolol (Bystolic)

Nebivolol is a beta blocker, but a particular one. It is the most selective agent at the beta-1 receptor that exists, and it additionally releases nitric oxide in the vascular endothelium. That combination is exactly what sets it apart from the classic members of the class.

Beta-1 selectivity means: it damps the adrenaline effect at the heart while largely leaving beta-2 receptors in bronchi and skeletal muscle alone. The NO effect widens the vessels and lowers peripheral resistance on top. For anyone training, that is the point where this substance separates from bisoprolol.

This information is for research and educational purposes only. No medical advice.

A classic beta blocker lowers blood pressure by throttling cardiac output: slower pulse, weaker contraction. The price is a capped maximum heart rate and with it measurably lower endurance performance. Anyone who used to sit at 180 may now reach 150.

Nebivolol does that too, but the NO component additionally lowers peripheral resistance. Part of the pressure reduction therefore does not come from braking the heart but from widening the vessels. In practice: the frequency brake is smaller at equal blood pressure reduction. It is not gone. Anyone doing cardio who still needs a beta blocker does best here, but there is no compromise-free option in this class.

SENIORS (European Heart Journal 2005) is the large outcome trial: over 2,100 patients aged 70 and above with heart failure, randomised to nebivolol or placebo. The combined endpoint of death and cardiovascular hospitalisation fell by 14 percent.

The echo substudy (European Heart Journal 2006) is more interesting in substance, because it showed the benefit appeared in both reduced and preserved ejection fraction. That is unusual, since most heart failure agents only convince in reduced function.

The NO mechanism is documented separately. The pharmacology review in the Journal of Clinical Hypertension (2007) summarises it, and the forearm investigation in the Journal of Pharmacology and Experimental Therapeutics showed directly in humans that the vasodilation runs through an L-arginine/NO dependent pathway. That is not a marketing claim, it was measured.

• Capped maximum heart rate: not a side effect as such, it is the mechanism. Cardio is affected more than lifting.
• Fatigue: typical in the first weeks, settles for many.
• Bradycardia: resting heart rate below 50 means the dose comes down.
• Cold hands and feet: less pronounced than with non-selective beta blockers, but present.
• Masked hypoglycaemia: beta blockers damp the warning signs. Relevant for diabetics.
• Rebound on stopping: hence always taper.

Store dry, at room temperature and protected from light. Keep out of reach of children.